Fig. 3From: Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncologyPercentage of activity linked to PC-3 cells in the absence (control—left blue bars) or in the presence of excess NOTA-PEG2-RM26 (blocked—right green, bars too low to be visible) for a [111In]In-AU-SAR-M1, b [111In]In-AU-SAR-M2 and c [111In]In-AU-SAR-M3 (**** = p < 0.0001)Back to article page